Twist Bioscience (TWST) is the centerpiece of Adam O’Dell’s Imperium pitch, the “silicon layer” of his DNA stack and the stock he frames as the next Intel of a coming revolution. It is a real company with real financials, which makes it the most substantive of the three teased names, and also the one where the valuation debate is sharpest. Here is the bull case, the bear case, and everything in between.
The Bull Case
The bull case starts with the technology. Twist’s NanoWell platform synthesizes DNA on silicon chips, an approach the presentation says “processes DNA at 10,000 times the speed of the previous technology.” We could not verify that 10,000-times figure, which is best read as a marketing number, but the underlying business is not hype. Twist has posted 15 consecutive quarters of revenue growth at roughly 20% a year, carries a market cap near $7.6 billion, and sits close to break-even on an adjusted cash-flow basis, with analysts modeling about $1.50 in adjusted earnings per share by fiscal 2028.
The customer list adds weight. Amazon, Microsoft, Johns Hopkins, Illumina, and DARPA all appear as partners or customers, and the AI angle is real: Twist uses AI to speed up DNA synthesis and protein discovery, with a high-profile Eli Lilly drug-discovery deal and an Anthropic collaboration that helped send the shares soaring late in the summer. Amazon’s DNA program picked Twist as its silicon layer alongside Ginkgo Bioworks (DNA) as its software layer, a concrete vote of confidence from a serious buyer.
The Bear Case
The bear case is about price. BWS Financial initiated coverage in September with a Sell rating and a $45 target, arguing Twist trades at a meaningful premium in a competitive tools market. Hunterbrook published a cautionary note whose headline question was blunt: “Last time TWST fell 95%. Could it happen again?” Both point at a rich valuation rather than a hidden bargain, and the teaser buy price of $112.00, which matches the November 17 close, means there is no tease-date discount to measure against.
The track record on this specific stock is also worth knowing. O’Dell has teased Twist since February 2021, when it was in the $120s, then swapped it out for Pacific Biosciences in the spring of 2024, a call that never worked out, and has now returned to it for this 2027 edition. That history does not make him wrong this time, but it does mean the thesis is a long-running, refreshable franchise.
The Verdict
O’Dell’s broader record gives the pitch credibility. He began teasing Palantir in the spring of 2024 when the stock was in the $20s, and it went on to be the best-performing stock in the S&P 500 for 2024. Twist is a legitimate, growing company with genuine partners, and the honest read is that the trend is worth owning while the certainty is not. For the software-layer counterpart, see our Ginkgo Bioworks stock piece, and for the apps-layer play, our Absci AI drug discovery teardown. To understand the write step itself, our DNA synthesis explainer covers the chemistry.
The Presenter’s Method
Adam O’Dell is the chief investment strategist at Money & Markets, the publishing house behind Green Zone Fortunes, and he also runs Cycle 9 Alert and 10X Profits. His method leans on the Green Zone Power Ratings, a quantitative system that scores stocks on momentum, value, and volatility and sorts them into a green zone of buys and a red zone of sells. That discipline is a real framework, not a gimmick, and it gives his recommendations a consistency that a lot of newsletter pitches lack.
The Size of the Claim
The presentation frames Twist as the next IBM, Intel, and Nvidia in sequence, with a real path to becoming the biggest company in the world while sitting “over 600 times smaller than Nvidia right now.” The implication is a 600-times runway. The honest read is different: a life-sciences tools business is not a chip monopoly, and being smaller than Nvidia is not, by itself, the opportunity.
The Offer
The pitch is “Imperium: The No. 1 Investment for 2027,” $297 a year with a 30-day refund. The Twist report is the centerpiece, carrying the “Beyond NVIDIA” framing, and it sits alongside the Ginkgo and Absci reports in the bundle. The teaser price of $112.00 matches the November 17 close, so there is no tease-date discount built into the pitch.
The Risk to Keep in Mind
The valuation debate is the one place the pitch and the skeptics genuinely disagree, and it is the reason to keep this on a watchlist rather than treat it as a sure thing. BWS Financial’s $45 target and Hunterbrook’s question about a repeat 95% drawdown both assume the market is paying too much for a tools company’s growth. The bull case assumes the AI and synthetic-biology demand keeps compounding. Both sides are looking at the same company; they just disagree on what the next few years of growth are worth.
The Takeaway
Twist is the rare newsletter pick that does not need a leap of faith on the business itself, only on the price. The technology is real, the customers are real, and the growth is real. Whether that adds up to a good entry point at $112 is a separate question, and it is the question worth answering before you act.
Ready to see the research? Click here to access Adam O’Dell’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.